LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Strona główna・Stock List・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Closed

SectorHealthcare

40.07 1.44

Buy Sell

Overview

Share price change

24h

Current

Min

38.97

Max

40.26

Key metrics
By Trading Economics
Income	-6.2M -91M
Profit margin	-867.293
Employees	316
EBITDA	-2.1M -96M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+38.15% upside

Market Stats
By TradingEconomics
Market Cap	-262M 3B
Previous open	38.63
Previous close	40.07

News Sentiment

By Acuity

67%

33%

328 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

34.81 / 38.24 Support & Resistance

Xenon Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 lis 2025, 21:34 UTC

Earnings

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 lis 2025, 23:45 UTC

Market Talk

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 lis 2025, 23:42 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 lis 2025, 23:41 UTC

Market Talk

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 lis 2025, 23:24 UTC

Earnings

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 lis 2025, 23:24 UTC

Earnings

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 lis 2025, 23:23 UTC

Earnings

JBS NV 3Q EPS 52c >JBS

13 lis 2025, 23:23 UTC

Earnings

JBS NV 3Q Sales $22.6B >JBS

13 lis 2025, 23:04 UTC

Market Talk

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 lis 2025, 22:02 UTC

Earnings

Nu Holdings 3Q Net $783M >NU

13 lis 2025, 22:01 UTC

Earnings

Nu Holdings 3Q Rev $4.2B >NU

13 lis 2025, 21:51 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 lis 2025, 21:50 UTC

Earnings

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 lis 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 lis 2025, 21:41 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 lis 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 lis 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 lis 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 lis 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 lis 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 lis 2025, 21:33 UTC

Market Talk

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 lis 2025, 21:33 UTC

Earnings

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 lis 2025, 21:31 UTC

Earnings

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 lis 2025, 21:25 UTC

Earnings

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 lis 2025, 21:25 UTC

Earnings

Figure Tech Solutions 3Q EPS 34c >FIGR

13 lis 2025, 21:23 UTC

Earnings

Intchains Group 3Q Rev $1.3M >ICG

13 lis 2025, 21:03 UTC

Earnings

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 lis 2025, 21:02 UTC

Earnings

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 lis 2025, 21:01 UTC

Earnings

Applied Materials 4Q Rev $6.8B >AMAT

13 lis 2025, 21:01 UTC

Earnings

Applied Materials 4Q Gross Margin 48.0% >AMAT

Peer Comparison

Price change

Xenon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

38.15% upside

12 Months Forecast

Average 55.15 USD 38.15%

High 65 USD

Low 44 USD

Based on 14 Wall Street analysts offering 12 month price targets forXenon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to Xenon Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

34.81 / 38.24Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

328 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.